Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Robert O. Dillman, Gabriel I. Nistor & Hans S. Keirstead. (2023) Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Robert O. Dillman, Gabriel I. Nistor & Aleksandra J. Poole. (2020) Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine. Human Vaccines & Immunotherapeutics 16:4, pages 742-755.
Read now
Read now
Gaetano Donofrio, Giulia Tebaldi, Stefania Lanzardo, Roberto Ruiu, Elisabetta Bolli, Andrea Ballatore, Valeria Rolih, Francesca Macchi, Laura Conti & Federica Cavallo. (2018) Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. OncoImmunology 7:12.
Read now
Read now
Margaret E. Gatti-Mays, Jason M. Redman, Julie M. Collins & Marijo Bilusic. (2017) Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Human Vaccines & Immunotherapeutics 13:11, pages 2561-2574.
Read now
Read now
Articles from other publishers (26)
Deepti Katiyar. (2023) Applications of intelligent biomaterials in cancer immunotherapy: A review. Materials Today: Proceedings.
Crossref
Crossref
Qiuyu Wu, Yuanhang Xia, Xiaohe Xiong, Xinxing Duan, Xiaoxiao Pang, Fugui Zhang, Song Tang, Junlei Su, Shuqiong Wen, Li Mei, Richard D. Cannon, Ping Ji & Zhanpeng Ou. (2023) Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors. Frontiers in Pharmacology 14.
Crossref
Crossref
Pei Huang & Hongzhang Deng. 2023. Immune Checkpoint Inhibitors - New Insights and Recent Progress. Immune Checkpoint Inhibitors - New Insights and Recent Progress.
Dalil Hannani, Estelle Leplus, Karine Laulagnier, Laurence Chaperot & Joël Plumas. (2023) Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines. Genes & Cancer 14, pages 3-11.
Crossref
Crossref
Natacha Jugniot, Jeremy J. Dahl & Ramasamy Paulmurugan. (2022) Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Crossref
Mahnaz Rezaei, Natalia D. Danilova, Mojdeh Soltani, Lyudmila V. Savvateeva, Vadim V. Tarasov, Mazdak Ganjalikhani-Hakemi, Alexandr V. Bazhin & Andrey A. Zamyatnin. (2022) Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and
Opportunities. Current Cancer Drug Targets 22:6, pages 437-453.
Crossref
Crossref
Juliana Sitta, Pier Paolo Claudio & Candace M. Howard. (2022) Virus-Based Immuno-Oncology Models. Biomedicines 10:6, pages 1441.
Crossref
Crossref
Reza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, Narges Baluch, Neda Ashayeri, Sushil Kumar, Hai-Ling Margaret Cheng, Herman Yeger, Bikul Das & Myron R. Szewczuk. (2021) The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers 13:14, pages 3596.
Crossref
Crossref
Patrick Santos & Fausto Almeida. (2021) Exosome-Based Vaccines: History, Current State, and Clinical Trials. Frontiers in Immunology 12.
Crossref
Crossref
Mengying He, Tao Yang, Yuhan Wang, Mengyuan Wang, Xingye Chen, Dawei Ding, Yiran Zheng & Huabing Chen. (2021) Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy. Advanced Healthcare Materials 10:9, pages 2002104.
Crossref
Crossref
Roza Nurieva, Margarita Divenko & Sang Kim. 2021. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy
3
29
.
Gabriel I. Nistor & Robert O. Dillman. (2020) Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial. Journal of Translational Medicine 18:1.
Crossref
Crossref
Fan Yang, Kun Shi, Yan-peng Jia, Ying Hao, Jin-rong Peng & Zhi-yong Qian. (2020) Advanced biomaterials for cancer immunotherapy. Acta Pharmacologica Sinica 41:7, pages 911-927.
Crossref
Crossref
Pierre Rosenbaum, Cécile Artaud, Sylvie Bay, Christelle Ganneau, Mario Campone, Suzette Delaloge, Carole Gourmelon, Delphine Loirat, Jacques Medioni, François Pein, Marie-Paule Sablin, Olivier Tredan, Andrea Varga & Claude Leclerc. (2020) The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. Cancer Immunology, Immunotherapy 69:5, pages 703-716.
Crossref
Crossref
Livia Neves Borgheti-Cardoso, Juliana Santos Rosa Viegas, Ana Vitoria Pupo Silvestrini, Angelo Luis Caron, Fabiola Garcia Praça, Marcelo Kravicz & Maria Vitória Lopes Badra Bentley. (2020) Nanotechnology approaches in the current therapy of skin cancer. Advanced Drug Delivery Reviews 153, pages 109-136.
Crossref
Crossref
Robert Owen Dillman & Candace Hsieh. (2019) Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment. Biomedicines 7:4, pages 80.
Crossref
Crossref
Jing Zhao, Ye Chen, Zhen-Yu Ding & Ji-Yan Liu. (2019) Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. Frontiers in Pharmacology 10.
Crossref
Crossref
Robert O. Dillman, Gabriel I. Nistor, Bryce T. McLelland, Candace Hsieh, Aleksandra J. Poole, Andrew N. Cornforth & Hans S. Keirstead. (2019) Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines. Oncotarget 10:51, pages 5359-5371.
Crossref
Crossref
Robert O Dillman, Andrew N Cornforth, Edward F McClay & Carol Depriest. (2019) Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. Melanoma Management 6:2, pages MMT20.
Crossref
Crossref
Rachel S. Riley, Carl H. June, Robert Langer & Michael J. Mitchell. (2019) Delivery technologies for cancer immunotherapy. Nature Reviews Drug Discovery 18:3, pages 175-196.
Crossref
Crossref
Robert O. Dillman, Andrew N. Cornforth, Gabriel I. Nistor, Edward F. McClay, Thomas T. Amatruda & Carol Depriest. (2018) Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Robert O. Dillman & Carol Depriest. (2018) Dendritic Cell Vaccines Presenting Autologous Tumor Antigens from Self-renewing Cancer Cells in Metastatic Renal Cell Carcinoma. Journal of Exploratory Research in Pharmacology 3:4, pages 93-101.
Crossref
Crossref
Fang Zheng, Jianzhong Dang, Hongyu Zhang, Fangzhou Xu, Diandian Ba, Bingyu Zhang, Fanjun Cheng, Alfred E. Chang, Max S. Wicha & Qiao Li. (2018) Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model. Journal of Immunotherapy 41:8, pages 361-368.
Crossref
Crossref
Robert O Dillman. (2017) An update on the relevance of vaccine research for the treatment of metastatic melanoma. Melanoma Management 4:4, pages 203-215.
Crossref
Crossref
Qiuju Han, Yaqun Wang, Min Pang & Jian Zhang. (2017) STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC. Journal of Experimental & Clinical Cancer Research 36:1.
Crossref
Crossref
Abhishek D. Garg, Pierre G. Coulie, Benoit J. Van den Eynde & Patrizia Agostinis. (2017) Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. Trends in Immunology 38:8, pages 577-593.
Crossref
Crossref